Product Name: GSK1349572
Dolutegravir (Tivicay) was a new kind of anti-ADIS drug that jointly developed by the British pharmaceutical giant
GlaxoSmithKline (GSK) with the Japanese Shionogi Pharmaceutical Company (Shionogi).
Dolutegravir (GSK1349572) is a HIV integrase inhibitor with an IC50 of 2.7 nM and is moderately effective against the significant
mutants Y143R, Q148K, N155H, and G140S/Q148H against Raltegravir.